Polyplus acquires Xpress Biologics, a Belgian contract development and manufacturing organization (CDMO) to expand its plasmid DNA engineering technology and services portfolio.

Strasbourg, France, 7 December 2022 – Polyplus, a leading solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, has announced the completed acquisition of Xpress Biologics, a Belgian contract development and manufacturing organization (CDMO) specialized in the production of plasmid DNA and protein using microbial expression systems. The acquisition will strategically expand the Polyplus plasmid DNA engineering technology and services portfolio. In addition, it will strengthen Polyplus’ leading position focused on improving gene-therapy viral vector upstream process economics and quality.

“Over the past few years, Polyplus has been evolving with the goal of enhancing process economics in the advanced therapies sector. This acquisition combines the expertise of the Xpress Biologics team with our existing expertise in transfection within the Cell and Gene Therapy market,” CEO of Polyplus, Mario Philips commented. “We will combine our deep understanding of the gene-therapy viral vector manufacturing process with research and High-Quality grade plasmid production immediately and expect to have the capability to supply GMP grade plasmids around Q1 of 2023.”

Xpress Biologics contract development and manufacturing services will continue to be offered for Research, GLP, High Quality and GMP grade proteins and plasmids DNA for therapeutic, vaccine and diagnostic applications including mRNA and viral vector based advanced therapies, while being leveraged for large-scale production of Polyplus proprietary plasmid DNA. The proprietary plasmid DNA constructs engineered by Polyplus are developed to increase AAV production yields and quality in conjunction with innovative transfection offers.

“Xpress Biologics was built with a range of technologies and services, including optimized expression systems, for pre-clinical production and, as of 2023, clinical productions of new biologics” said Marc Daukandt, CEO at Xpress Biologics. “We see this acquisition as the next step forward in bringing our enabling technologies and products to the global market and help move advanced therapy discovery and commercialization forward.”


About Xpress Biologics

Xpress Biologics is a Belgian contract development and manufacturing organization (CDMO) specialized in the production of plasmid DNA and protein using bacteria and yeast expression systems. The company launched in 2014 with the mission of improving the value chain of drug development for Academics, Biotech and Pharma companies from R&D to manufacturing. Core applications for the technology and services include human and veterinary vaccines and biotherapeutics, as well as diagnostics.

About Polyplus

Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro® and FectoVIR®-AAV. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia.


Media Contact Information: 

Alengo Nyamay’antu, PhD
Marketing & Communication team leader at Polyplus
Direct: +33 3 88 67 59 38